Antihypertensive therapy is aimed at improving vascular and cardiac health, as well as lowering blood pressure (BP). The benefit of such drugs in untreated patients with borderline BP has not been demonstrated. Subjects with BPs X130 mm Hg systolic or X85 mm Hg diastolic and at least one additional risk factor were randomly assigned to treatment with carvedilol, lisinopril, their combination or placebo. Cardiovascular health was assessed by a disease score (DS), which combines the following tests of cardiovascular function and structure: resting BP, large-and small-artery elasticity (SAE), BP response to exercise, retinal vasculature analysis, electrocardiogram, carotid intima-medial thickness, left ventricular mass, microalbuminuria and N-terminal pro B-type natriuretic peptide. DS was assessed at baseline, after 3 and 9 months of therapy and 1 month after discontinuation of therapy. All active treatment groups displayed a sustained reduction in BP during 9 months of treatment, with the greatest reduction in the cardvedilol þ lisinopril group. DS and SAE improved in all the treatment groups but the changes were of borderline significance and exhibited no evidence for progressive improvement from 3 months (functional) to 9 months (structural). All changes were reversed within 1 month after discontinuation of therapy. We conclude that 9 months of treatment with carvedilol, lisinopril or their combination produce a sustained and well-tolerated functional improvement but not a structural improvement, perhaps because of a lack of the nitric oxide-enhancing effects of other agents that inhibit structural changes in the vasculature.
INTRODUCTION
The target for antihypertensive therapy has been blood pressure (BP) reduction, but the ultimate goal of this therapy is to preserve the health of the vasculature and heart. 1 Long-term trials of antihypertensive therapy have documented the vascular and cardiac protective effects of drugs that lower BP. [2] [3] [4] [5] In recent trials it has become apparent that some BP-lowering regimens are more effective than others in preventing morbid events, [6] [7] [8] [9] presumably because of differences in vascular or cardiac protection.
Drugs can favorably affect the cardiovascular system by lowering arterial pressure, by inhibiting mediators of vascular or cardiac growth and remodeling, and by enhancing the protective effect of endothelial function. 10 , 11 The greater reduction in morbidity observed in response to renin-angiotensin inhibitors than to diuretics or b-blockers, 6, 9, 12 despite similar BP reduction, has been attributed to the beneficial effects of reduced angiotensin II levels and to the endothelial-protective effect of inhibition of the renin-angiotensin system. 13 Similarly, the failure of alpha receptor blockade to favorably affect outcomes, 14, 15 despite its BP-lowering effect, can be attributed to a lack of protective vascular and cardiac properties.
Although the relationship between BP and morbid events is continuous at all levels of BP, [16] [17] [18] management guidelines advocate drug treatment only at levels that exceed certain thresholds. 19 Thus, individuals whose pressures are below these thresholds are generally not treated with antihypertensive drugs, even though many go on to suffer morbid events without manifesting hypertensive BPs. 20 In such patients, vascular and cardiac protection rather than BP reduction must serve as the target for therapy.
We have developed a screening program that assesses, with 10 non-invasive tests, abnormalities of function and structure in the large arteries, small arteries and left ventricle. 21, 22 A disease score (DS) based on these tests has demonstrated striking discriminatory value in predicting risk of future morbid events. 23 The goal of DETECT (DEtection and Treatment of Early Cardiovascular disease Trial) was to evaluate the effects on vascular and cardiac health of an angiotensin-converting enzyme (ACE) inhibitor, lisinopril and a third-generation b-blocker, carvedilol, separately and together, vs placebo in individuals with BPs at a level that they or their care providers did not think justified antihypertensive therapy. Assessments of vascular and cardiac health were scheduled at 3 and 9 months of therapy in order to separate early functional from delayed structural effects of the drugs. Furthermore, an additional study 1 month after withdrawal of therapy was designed to determine if changes persisted, as they would with structural effects.
SUBJECTS AND METHODS Subjects
DETECT was a single-center, double-blind study that enrolled men and women 18 years of age or older who had prehypertensive or borderline hypertensive BPs (X130 mm Hg systolic or X85 mm Hg diastolic) and were not taking antihypertensive therapy. Subjects also had at least one of the following risk factors: low-density lipoprotein cholesterol between 130-160 mg dl À 1 , high-density lipoprotein cholesterolo40 mg dl À 1 , fasting blood glucose between 110-126 mg dl À 1 , body mass index X30 kg m À 2 , current smoker or family history of premature heart disease or hypertension.
Exclusion criteria included previous cardiovascular events, current pregnancy or lactation, current use of antihypertensive or other cardiac medications, and other serious medical conditions. Concomitant use of other antihypertensive or cardiac medications during the study was prohibited.
A variable block randomization scheme was used to randomize subjects to one of the following treatment groups at the baseline visit: (1) carvedilol CR þ lisinopril, (2) carvedilol CR þ placebo, (3) lisinopril þ placebo or (4) placebo þ placebo. Initiation doses for active medications were 20 mg carvedilol CR and 10 mg lisinopril. After 1 month, the dose was increased to 40 mg carvedilol CR and 20 mg lisinopril. Seven subjects were returned to the initiation dose after reporting intolerable side-effects such as orthostasis and fatigue (two subjects on combination therapy and five subjects on monotherapy). Subjects received either study medication or placebo for 9 months and returned at 10 months (1 month after discontinuation of treatment) for a final assessment.
A total of 101 eligible subjects were enrolled in the trial and 91 completed the study. The protocol was approved by the University of Minnesota Institutional Review Board and all the participants gave written informed consent.
Methods
The 10 components of the DS were selected because of their ability to quantify early functional and structural abnormalities of the vasculature and left ventricle. [21] [22] [23] Parameters were assessed at baseline, after 3 and 9 months of study treatment, and 1 month after discontinuation of study treatment (10 months) . Parameter values for all subjects were measured and recorded by a single observer. Quantitative results from these tests were also converted into categorical classifications based on values stratified by age and gender as described previously. 21 , 22 The categorical data were scored as follows: normal ¼ 0 points, borderline ¼ 1 point, abnormal ¼ 2 points. Point values from all parameters were summed to create the DS, with values ranging from 0 to 20. DS tests included the following:
Small-and large-artery elasticity: Radial artery pulse waves and BP were measured with the HDI Pulsewave CR-2000 (Hypertension Diagnostics Inc., Eagan, MN, USA) and used to calculate small-artery elasticity (SAE) and large-artery elasticity (LAE) using pulse contour analysis.
Resting BP: Four consecutive sitting BP measurements were taken on each arm using an automated sphygmomanometer, (Omron HEM-780, Kyoto, Japan) at the baseline visit. The arm with higher average BP was used for subsequent resting BP measurements.
Exercise BP: BPs were taken before, during and after exercise using standard sphygmomanometry while the subject was standing. The patient walked on a treadmill for 3 min at a workload of 5 metabolic equivalents of task (METS) using settings of 2.3 m.p.h. and 7% incline. Absolute exercise BP values, as well as the magnitude of BP change were used to determine the score.
Retinal analysis: Optic fundus photos were taken with a digital camera and analyzed for artery-vein (A:V) crossing changes. EyeScape software (Synemed, Benicia, CA, USA) was used to measure A:V ratios at multiple sites and calculate an average A:V ratio.
Electrocardiography: A standard 12-lead electrocardiogram was evaluated for evidence of hypertrophy, repolarization abnormalities or conduction abnormalities.
Carotid intimal-media thickness: Ultrasound equipment (Sonosite Inc., Bothell, WA, USA) was used to measure intimal-media thickness 1 cm distal to the carotid bulb and to identify localized carotid plaques.
Left ventricular mass: Left ventricular (LV) ultrasound was performed using Sonosite equipment and LV mass was calculated using the Devereux formula.
Microalbuminuria: A urine sample was analyzed for albumin/creatinine ratio by blanked end point methodology.
N-terminal pro B-type natriuretic peptide: A venous blood sample was analyzed for plasma N-terminal pro B-type natriuretic peptide by chemiluminescence (Ortho Clinical Diagnostics, Rochester, NY, USA).
Metabolic parameters (not included in DS): A fasting venous blood sample was used to measure total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein and glucose by non-high-density lipoprotein precipitation with phosphotungstic acid and magnesium chloride, colorimetric reflectance spectrophotometry and glucose oxidase methodology.
Statistical analysis
Variables are presented as mean values±s.d. or s.e. as indicated in data tables. Analysis of variance was used to compare DS and changes in continuous variables across the treatment groups. P-values reported are from the 3-df test comparing all groups. Pair-wise analysis between the active treatment groups and placebo was also utilized. All reported P-values are based on two-sided tests with a significance level of a ¼ 0.05. SAS version 9.2 statistical software (Cary, NC, USA) was used for data analysis.
RESULTS
Of the 91 subjects who completed the study 23 received carvedilol CR þ linisinopril (C þ L), 24 received carvedilol CR þ placebo (C), 21 received lisinopril þ placebo (L) and 23 received placebo þ placebo (P). Ten subjects dropped out before completion, one due to an allergic reaction attributed to study medication, five because of unrelated medical complications and four because of withdrawn consent. Therapy was well-tolerated with only seven subjects (7.7%) requiring down-titration to initiation levels due to side-effects. Average compliance (determined by pill counts) was 95.7% and did not differ between groups.
Baseline demographic and clinical characteristics were similar between the treatment groups ( Table 1) . Baseline DS values for all the treatment groups were also similar ( Table 2) .
After 3 months of therapy, significant differences were observed among groups for changes in the DS (P ¼ 0.01) (Figure 1a) , systolic Table 1 . Baseline demographics of study population (n ¼ 91) BP and diastolic BP (P ¼ o0.001) ( Table 3) . On pair-wise analysis all the active treatment groups displayed a reduction in BP compared with placebo, but the fall in pressure in the C þ L group exceeded that in the C or L groups (Po0.05) ( Table 3) . SAE and LAE increased in all the active treatment groups compared with placebo, but the increase did not reach statistical significance by analysis of variance. After 9 months of therapy changes in DS among the treatment groups approached but did not achieve statistical significance (P ¼ 0.057) (Figure 1a ). The trend for DS improvement could be attributed largely to the known BP-lowering effect of lisinopril and carvedilol. The systolic and diastolic BP decline in the three active treatment groups compared with placebo was maintained at 9 months (Po0.002 and Po0.004, respectively). Changes in SAE at 9 months were significantly different between the treatment groups (P ¼ 0.036) with increases in all the treatment groups vs placebo. Lisinopril monotherapy showed the greatest improvement from baseline (31% increase); combination therapy, 22% increase; carvedilol therapy, 19% increase; and placebo, 4% decrease. Figure 1b shows the change in SAE over time. No progressive increase in SAE from 3 to 9 months was observed in any treatment group, including the two groups receiving lisinopril. A trend for improvement in LAE at all time points with active treatment was also observed (P ¼ 0.064).
NT-pro BNP levels were higher (Po0.05) in the treatment groups (Table 3) because of the effect of carvedilol, presumably as a result of more prolonged diastolic cardiac filling time. LV mass reduction displayed a trend toward greater improvement with combination therapy but remained slightly above significance thresholds by analysis of variance (P ¼ 0.070).
One month after discontinuation of study drugs, all changes, including BP, had returned to baseline levels (Table 3) .
DISCUSSION
The beneficial effect of antihypertensive drugs on vascular and cardiac health is in part dependent on a fall in BP but is also related to direct effects of the drugs. The most important and wellstudied property of protective drugs is their ability to enhance endothelial function or nitric oxide protection. 11, 24 When BP is within the normal range, the benefit of antihypertensive drugs on cardiovascular morbidity and mortality is particularly dependent on direct vascular and cardiac effects. These cardiovascular effects likely account at least in part for the favorable effect of inhibitors of the renin-angiotensin system on outcomes in heart failure [25] [26] [27] and atherosclerosis. 28, 29 As patients with prehypertensive or borderline BPs are usually not treated with antihypertensive drugs we carried out a study to evaluate the vascular and cardiac effects of 9 months of therapy with an ACE inhibitor, lisinopril and/or a b-blocker with additional vasodilator properties, carvedilol, in untreated individuals with borderline BPs. These drugs were effective in producing a sustained and well-tolerated reduction in BP, but they did not appear to induce favorable long-term effects on vascular or cardiac structure. SAE and large-artery compliance or elasticity increased early and the increase persisted with all three drug regimens compared with placebo. The increase in SAE can be attributed to the relaxing effect of both pharmacological agents on the small arteries, which influence the reflected waves that contribute to the calculation of SAE. 30 This small-artery dilation is a known effect of ACE inhibitors, but its demonstration with carvedilol confirms that this b-blocker has vasodilator properties not present with most b-blockers. 31 The increase in LAE is anticipated with any BP-lowering intervention because the non-linear pressure:volume relationship in the large conduit arteries mandates a direct relationship between pressure reduction and compliance increase. These functional vascular effects, however, did not appear to be enhanced by additional structural changes over 9 months of therapy, and the vascular and BP changes were entirely reversed within a month after treatment was stopped. Furthermore, LV mass did not fall significantly despite the BP reduction.
In a previous study, we demonstrated in a similar population a favorable effect of the angiotensin receptor blocker valsartan compared with placebo on vascular and cardiac health. In that trial, DEtection and Treatment of Early Cardiovascular disease Trial: Intervention with Valsartan (DETECTIV), 12 months of valsartan therapy induced a greater improvement in arterial compliance than 6 months, with the SAE increase from baseline to 12 months averaging over 70%. The drug also produced a significant decline in LV mass. 32 In the TRial Of Prevention of HYpertension (TROPHY), which recruited a similar population of prehypertensive individuals, 2 years of therapy with the angiotensin receptor blocker candesartan produced a sustained reduction in BP, which persisted for 2 years after the drug was withdrawn. 33 These observations raise the possibility that sustained angiotensin receptor blocker therapy produces a favorable structural effect that persists after the drug is withdrawn. ACE inhibitor therapy would be expected, on the basis of long-term outcome trials, 28, 29 also to exert beneficial effects on structure. However, lisinopril, a drug that may not share the tissue effects of ramipril, perindopril and quinapril, 34 has not been exposed to such long-term studies. The failure of lisinopril to demonstrate superiority over diuretic therapy in ALLHAT 35 could also reflect inferiority of lisinopril on the tissue renin-angiotensin system.
Carvedilol is a non-selective b-blocker with additional vasodilator activity predominantly related to alpha adrenoceptor blockade. In previous trials alpha blockade has been ineffective in reducing mortality in heart failure or hypertension 13, 14 and has not been shown to enhance endothelial function.
The increase in SAE observed in this and previous drug trials is of particular importance as a marker of vascular function, because it serves as a surrogate marker of endothelial function. 36 Previously we showed that reduced SAE but not LAE is an independent early risk marker for cardiovascular events. 37 Recently, data from the Multi-Ethnic Atherosclerosis Study demonstrated that SAE is one of the strongest predictors of incident arterial hypertension among a variety of functional and structural measures of the vasculature. 38 SAE can increase as a result of functional vasodilation, such as nitric oxide enhancement or norepinephrine or angiotensin inhibition, or by reversal of structural remodeling. 39 As vasodilation should occur early in pharmacologic studies, and structural changes should be delayed, the 3 and 9 month study time points were designed to separate functional from possible structural effects of the drug administration. In DETECT there was no evidence to support an additional structural vascular effect in addition to the early functional effect. Table 3 . Change in study parameters after 9 months of therapy and following a 1-month washout period Abbreviations: D 0-9, change in parameters from baseline after treatment for 9 months; D 0-10, change in parameters from baseline after treatment for 9 months and 1 month medication washout; carotid IMT, carotid intimal-media thickness; ECG score, electrocardiogram score; DBP, diastolic blood pressure; DS, disease score; LAE, large-artery elasticity; LV mass, left ventricle mass; NT-proBNP, N-terminal pro B-type natriuretic peptide; retinal AV ratio, retinal artery to vein size ratio; SAE, small-artery elasticity; SBP, systolic blood pressure. Data are presented as mean change ± s.d.
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Differences in duration of therapy could be a factor in these observations. The DETECTIV trial assessed 12 months of therapy whereas DETECT was confined to 9 months. It is possible that an additional 3 months of treatment could have induced structural changes not observed in this study. Indeed, the sustained BP reduction in the TRial Of Prevention of HYpertension (TROPHY) after the drug was withdrawn was observed after 2 years of treatment.
A study design difference between DETECTIV and DETECT could also have contributed to the apparent differences in response to valsartan compared with lisinopril and carvedilol. The entrance criteria for DETECTIV included a DS of 6 or greater in order to recruit individuals with more advanced vascular disease. An unwanted consequence of that strategy was the expected regression to a mean that resulted in a reduction of DS on the subsequent visit (placebo effect). In DETECT we sought instead to recruit individuals with increased risk for disease by including dyslipidemia, prediabetic blood sugars, obesity or a family history of premature cardiovascular disease as entry requirements. As a high DS was not an entrance requirement, the study population in DETECT had less severe early disease, with baseline DS averaging 6.3 as compared with 8.8 in DETECTIV. Both SAE and LAE were also higher in DETECT. The greater long-term benefit with valsartan thus could be a consequence of greater severity of baseline disease. Further studies are, therefore, necessary before we can conclude that neither lisinopril nor carvedilol produce direct structural vascular effects that supplement their BP-lowering properties.
The patients selected for study in DETECT were not being treated for hypertension. Some had baseline BPs that exceeded thresholds for treatment recommendation. The subjects elected to participate in the study and, therefore, do not represent a random sampling of the population with borderline or mildly elevated pressures. The fact that they were not receiving antihypertensive therapy is not surprising in view of national statistics suggesting inadequate hypertension treatment. 40 The decision not to treat may represent variability of clinic pressures and physician or patient reluctance. As the placebo group exhibited a sustained decrease in BP averaging 9.7/6.8 mm Hg the need for drug therapy to reduce BP below the treatment threshold could be questioned. This variability of BP, which is used to guide therapeutic decisions, lends further support to the concept that the blood vessel not the BP should be the target for therapy. 1 What is known about this topic ACE inhibitors and b-blockers lower BP, but the goal of therapy, especially in those with high-normal pressures or borderline BPs, must be to improve cardiovascular structure. Current guidelines, aimed at treating individuals with BPs above an arbitrary threshold, exclude from therapy many subjects who have early disease likely to progress to morbid events.
What this study adds Lisinopril and carvedilol, alone or together, produce a well-tolerated reduction in BP in a population with high-normal or borderline elevated pressures. The functional vascular response to these drugs is not augmented by a structural benefit over 9 months of treatment.
Whether inadequate duration of therapy or the mechanism of action of these specific drugs accounts for the deficient structural response requires further study.
